FrancophonIA/ELRC3.0 huggingface dataset:
English: Bactericidal antibodies against these strains were measured by the Serum Bactericidal Assay using human serum as the source of complement (hSBA).
Croatian: Baktericidna protutijela na te sojeve izmjerena su testom baktericidnosti seruma, s humanim serumom kao izvorom komplementa (hSBA).
English: Following Bexsero vaccination, a high percentage of subjects were seropositive and achieved 4-fold increases in hSBA titers independent of pre-vaccination status.
Croatian: Nakon cijepljenja Bexserom veliki postotak ispitanika bio je seropozitivan i postigao je četverostruko povećanje titra hSBA neovisno o statusu prije cijepljenja.
English: The immunogenicity after two doses has been also documented in another study in infants 6 months to 8 months of age at enrolment (see Table 4).
Croatian: Imunogenost nakon dvije doze također je dokumentirana u drugom ispitivanju u dojenčadi u dobi od 6 do 8 mjeseci prilikom uključivanja (vidjeti Tablicu 4).
English: At 1 month following the 2-dose vaccination course, the percentages of subjects with hSBA ≥1:5 in individuals with complement deficiencies and asplenia or splenic dysfunction were 87% and 97% for antigen fHbp, 95% and 100% for antigen NadA, 68% and 86% for antigen PorA P1.4, 73% and 94% for antigen NHBA, respectively, indicating an immune response in these immunocompromised subjects.
Croatian: Mjesec dana nakon sheme cijepljenja s 2 doze, postotci ispitanika s hSBA ≥1:5 u osoba s nedostacima komplementa i asplenijom ili poremećajima funkacije slezene bili su 87% odnosno 97% za antigen fHbp, 95% odnosno 100% za antigen NadA, 68% odnosno 86% za antigen PorA P1.4, 73% odnosno 94% za antigen NHBA, što upućuje na imunološki odgovor u tih imunokompromitiranih ispitanika.
English: Yes, one dose with an interval of 12 months to 23 months between the primary series and booster dose c
Croatian: Da, jedna doza s intervalom od 12 mjeseci do 23 mjeseca između primarne serije i booster doze c
English: As with any vaccine, vaccination with Bexsero may not protect all vaccine recipients.
Croatian: Kao i kod drugih cjepiva, cijepljenje Bexserom možda neće zaštititi sve cijepljene osobe.
English: Neck stiffness or uncomfortable sensitivity to light (photophobia), indicating meningeal irritation, has been sporadically reported shortly after vaccination; these symptoms have been of mild and transient nature.
Croatian: Ukočenost vrata ili neugodna osjetljivost na svjetlost (fotofobija) koji ukazuju na meningealnu iritaciju prijavljeni su sporadično ubrzo nakon cijepljenja; ti su simptomi bili blage i prolazne prirode.
English: Against each of the vaccine antigens, seroresponse rates and hSBA GMTs were high and similar after the two-dose series in infants 6-8 months of age and children 13-15 months of age.
Croatian: 4. Stope seroloških odgovora i hSBA GMTs za svaki od antigena cjepiva bile su visoke i slične nakon primanja dvije doze u dojenčadi u dobi od 6 do 8 mjeseci i djece u dobi od 13 do 15 mjeseci.
English: Study V72P13 2, 4, 6 months
Croatian: Studija V72P13 2, 4, 6 mjeseci
English: Uncommon: fever (≥40°C)
Croatian: - vrućica (≥38 ºC)
English: Study V72P16 2, 3, 4 months fHbp
Croatian: Studija V72P16 2, 3, 4 mjeseca fHbp
English: * % seropositive = the percentage of subjects who achieved an hSBA ≥ 1:4 (against reference strains for fHbp, NadA, PorA P1.4 antigens) and an hSBA ≥ 1:5 (against reference strain for NHBA antigen).
Croatian: * % seropozitivnih = postotak ispitanika koji su postigli hSBA ≥ 1:4 (protiv referentnih sojeva za antigene fHbp, NadA i PorA P1.4) i hSBA ≥ 1:5 (protiv referentnih sojeva za antigen NHBA) ** GMT = geometrijska sredina titra.
English: % seropositive (95% CI) hSBA GMT (95% CI) * % seropositive = the percentage of subjects who achieved an hSBA ≥ 1:4 (in the 6 to 11 months range of age) and an hSBA ≥ 1:5 (in the 12 to 23 months range of age).
Croatian: % seropozitivnih (95% CI) hSBA GMT (95% CI) * % seropozitivnih = postotak ispitanika koji su postigli hSBA ≥ 1:4 (u dobnom rasponu od 6 do 11 mjeseci) i hSBA ≥ 1:5 (u dobnom rasponu od 12 do 23 mjeseca).
English: When given at the same time with other vaccines Bexsero must be given at separate injection sites.
Croatian: Kada se daje istodobno s drugim cjepivima, Bexsero se mora primijeniti na zasebnom mjestu injiciranja.
English: Immunisation with Bexsero is intended to stimulate the production of bactericidal antibodies that recognize the vaccine antigens NHBA, NadA, fHbp, and PorA P1.4 (the immunodominant antigen present in the OMV component) and are expected to be protective against Invasive Meningococcal Disease (IMD).
Croatian: Imunizacija Bexserom namijenjena je stimulaciji stvaranja baktericidnih protutijela koja prepoznaju antigene cjepiva NHBA, NadA, fHbp i PorA P1.4 (imunodominantan antigen prisutan u OMV
English: The same extension study also evaluated antibody persistence and the response to a booster dose in children who received the two-dose primary series at 2-5 or 6-10 years of age.
Croatian: U istom nastavku ispitivanja ocjenjivala se i postojanost protutijela te odgovor na booster dozu u djece koja su primila dvije doze primarne serije imunizacije u dobi od 2 do 5 ili u dobi od 6 do 10 godina.
English: Bellaria-Rosia 53018 Sovicille (Siena) Italy.
Croatian: GSK Vaccines S.r.l. Bellaria-Rosia 53018 Sovicille (Siena) Italija.
English: Immunogenicity in infants 6 to 11 months and children 12 to 23 months of age
Croatian: Imunogenost u dojenčadi u dobi od 6 do 11 mjeseci te u djece u dobi od 12 do 23 mjeseca
English: associated with a skin rash on the trunk of the body, and sometimes followed by a peeling of the skin on the hands and fingers, swollen glands in the neck, red eyes, lips, throat and tongue - Itchy rash, skin rash
Croatian: - Kawasakijeva bolest koja može uključivati simptome kao što su vrućica koja traje dulje od pet dana, povezana s osipom kože na trupu tijela nakon čega katkada slijedi guljenje kože na rukama i prstima, otečene žlijezde na vratu, crvenilo očiju, usana, grla i jezika - osip praćen svrbežom, osip na koži
English: Very common: headache
Croatian: - proljev - glavobolja
English: 35 to 47 months of age 4 to 7 years of age 8 to10 years of age fHbp
Croatian: 4 do 7 godina 8 do 10 godina fHbp
English: - A booster will be given between 12 months and 15 months of age after an interval of at least 6 months from the last injection of the initial course.
Croatian: Docjepljivanje će se primijeniti u dobi od 12 do 15 mjeseci, nakon što prođe najmanje 6 mjeseci od posljednje injekcije u sklopu osnovnog cijepljenja.
English: Infants, 2 months to 5 months a
Croatian: Dojenčad, 2 mjeseca do 5 mjeseci a
English: - The interval between each injection should be at least 2 months.
Croatian: - Razmak između injekcija treba biti najmanje 2 mjeseca.
English: Study V72P12 2, 3, 4 months
Croatian: Studija V72P12 2, 3, 4 mjeseca
English: In the same study the response to an additional dose administered 2 to 3 years after the booster was indicative of immunological memory as shown by a robust antibody response against all Bexsero antigens, ranging from 81% to 100% and from 70% to 99%, respectively.
Croatian: U istom je ispitivanju odgovor na dodatnu dozu primijenjenu 2 - 3 godine nakon booster doze upućivao na imunološko pamćenje, što je pokazao robustan odgovor protutijela na sve antigene sadržane u Bexseru, koji se kretao u rasponu od 81% do 100% odnosno u rasponu od 70% do 99%.
English: Yes, one dose in the second year of life with an interval of at least 2 months between the primary series and booster dose c
Croatian: Da, jedna doza u drugoj godini života, s intervalom od najmanje 2 mjeseca između primarne serije i booster doze c
English: - The first injection should be given no earlier than 3 months of age if two initial doses are given; the interval between injections should be at least 2 months.
Croatian: - Prvu injekciju treba dati najranije u dobi od 3 mjeseca ako se za osnovno cijepljenje primjenjuju dvije doze; razmak između injekcija treba biti najmanje 2 mjeseca.
English: Yes, one dose between 12 and 15 months of age with an interval of at least 6 months between the primary series and booster dose b, c
Croatian: Da, jedna doza u dobi između 12 i 15 mjeseci, s intervalom od najmanje 6 mjeseci između primarne serije i booster doze b, c
English: - The first injection should be given no earlier than 2 months of age if three initial doses are given; the interval between injections should be at least 1 month.
Croatian: - Prvu injekciju treba dati najranije u dobi od 2 mjeseca ako se za osnovno cijepljenje primjenjuju tri doze; razmak između injekcija treba biti najmanje 1 mjesec.
English: 2, 4, 6, 12 months fHbp pre-booster* % seropositive** (95% CI) hSBA GMT*** (95% CI)
Croatian: 2, 4, 6, 12 mjeseci fHbp prije boostera* % seropozitivnih** (95% CI) hSBA GMT*** (95% CI)
English: Bellaria-Rosia IT-53018 Sovicille-Siena Italy
Croatian: GSK Vaccines S.r.l. Bellaria-Rosia IT-53018 Sovicille-Siena Italija
English: Your child should receive an initial course of two or three injections of the vaccine followed by an additional injection (booster).
Croatian: Vaše dijete treba primiti osnovno cijepljenje od dvije ili tri injekcije cjepiva i nakon toga još jednu dodatnu injekciju (docjepljivanje).
English: The immunogenicity after two doses of Bexsero administered either one or two months apart in children 2 to 10 years of age has been evaluated in an initial phase 3 clinical study and its extension.
Croatian: Imunogenost nakon dvije doze Bexera primijenjene u razmaku od jednog ili dva mjeseca u djece u dobi od 2 do 10 godina ocjenjivala se u inicijalnom kliničkom ispitivanju faze 3 i nastavku tog ispitivanja.
English: Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, varicella, and meningococcal groups A, C, W, Y conjugate.
Croatian: Bexsero se može primjenjivati istodobno s bilo kojim antigenom sljedećih cjepiva, bilo kao monovalentno ili kao kombinirano cjepivo protiv: difterije, tetanusa, pertusisa (nestanično), hemofilusa tipa b, poliomijelitisa (inaktivirano), hepatitisa B, pneumokoka (sedmerovalentno, konjugirano), morbila, parotitisa, rubele, varičela i meningokoka (konjugirano grupe A, C, W, Y).
English: 6.6 Special precautions for disposal and other handling Upon storage a fine off-white deposit may be observed in the pre-filled syringe containing the suspension.
Croatian: 6.6 Posebne mjere za zbrinjavanje i druga rukovanja lijekom Pri čuvanju lijeka, u napunjenoj štrcaljki koja sadrži suspenziju može se primijetiti tanak bjelkasti sloj.
English: In infant studies, participants received three doses of Bexsero either at 2, 4 and 6 or 2, 3 and 4 months of age and a booster dose in their second year of life, as early as 12 months of age.
Croatian: U ispitivanjima u dojenčadi ispitanici su primali tri doze Bexsera u dobi od 2, 4 i 6 mjeseci ili 2, 3 i 4 mjeseca te booster dozu u drugoj godini života, već u dobi od 12 mjeseci.
English: The response to a booster dose administered 24-36 months after the primary series was indicative of immunological memory as the percentages of seropositive subjects ranged across strains from 93% to 100% in children 4-7 years of age and from 96% to 100% in children 8-12 years of age.
Croatian: Odgovor na booster dozu primijenjenu 24 - 36 mjeseci nakon primarne serije ukazivao je na imunološko pamćenje jer su postoci seropozitivnih ispitanika kod svih sojeva iznosili od 93% do 100% u djece u dobi od 4 do 7 godina te od 96% do 100% u djece u dobi od 8 do 12 godina.
English: Bexsero is given to individuals from 2 months of age and older to help protect against disease caused by the Neisseria meningitidis group B bacteria.
Croatian: Bexsero se daje osobama u dobi od 2 mjeseca i starijima za zaštitu od bolesti uzrokovane bakterijom Neisseria meningitidis grupe B.
English: The percentages of seropositive subjects (i.e. achieving an hSBA of at least 1:4) across strains ranged from 46% to 95% at one month after the first dose and from 69% to 100% at one month after the second dose (Table 6).
Croatian: Postoci seropozitivnih ispitanika (tj. onih koji su postigli hSBA od najmanje 1:4) kod svih sojeva kretali su se od 46% do 95% mjesec dana nakon prve doze te od 69% do 100% mjesec dana nakon druge doze (Tablica 6).
English: 0, 2 months fHbp
Croatian: 0, 2 mjeseca fHbp
English: Infants, 6 months to 11 months
Croatian: Dojenčad, 6 mjeseci do 11 mjeseci
English: Not known: hypotonic-hyporesponsive episode, meningeal irritation (signs of meningeal irritation, such as neck stiffness or photophobia, have been sporadically reported shortly after vaccination.
Croatian: Nepoznato: hipotonično-hiporesponzivna epizoda, meningealna iritacija (znakovi meningealne iritacije kao što su ukočenost vrata ili fotofobija prijavljeni su sporadično ubrzo nakon cijepljenja.
English: Fever (adolescents from 11 years of age and adults).
Croatian: Vrućica (adolescenti od 11 godina i odrasli).
English: What you need to know before you or your child receive BEXSERO
Croatian: Što morate znati prije nego vi ili vaše dijete primite BEXSERO NEMOJTE primiti Bexsero:
English: Injection site reactions like extensive swelling of the vaccinated limb, blisters at or around the injection site and hard lump at the injection site (which may persist for more than one month).
Croatian: Reakcije na mjestu injiciranja poput opsežnog oticanja cijepljenih udova, mjehurići na mjestu injiciranja ili oko njega i tvrda kvržica na mjestu injiciranja (koja može trajati dulje od mjesec dana).
English: Immunogenicity in adolescents (from 11 years of age) and adults
Croatian: Imunogenost u adolescenata (u dobi od 11 godina) i odraslih
English: Should concomitant administration of other vaccines be necessary, vaccines must be administered at separate injection sites.
Croatian: Kada je potrebna istodobna primjena s drugim cjepivima, cjepiva se moraju primijeniti na zasebnim mjestima injiciranja.
English: * pre-booster time point represents persistence of bactericidal antibody at 8 months after Bexsero vaccination at 2, 3 and 4 months of age and 6 months after Bexsero vaccination at 2, 4 and 6 months of age.
Croatian: * vremenska točka prije boostera pokazuje postojanost baktericidnih protutijela 8 mjeseci nakon cijepljenja Bexserom u dobi od 2, 3 i 4 mjeseca i 6 mjeseci nakon cijepljenja Bexserom u dobi od 2, 4 i 6 mjeseci.
English: Rare: urticaria
Croatian: Rijetko: urtikarija
English: In the extension study, in which two doses of Bexsero were administered one month apart in unvaccinated children, high percentages of subjects were seropositive one month after the second dose.
Croatian: U nastavku ispitivanja, u kojem su necijepljenoj djeci primijenjene dvije doze Bexsera u razmaku od mjesec dana, zabilježeni su visoki postoci seropozitivnih ispitanika mjesec dana nakon primjene druge doze.
English: Gastrointestinal disorders Very common: diarrhoea, vomiting (uncommon after booster)
Croatian: Poremećaji probavnog sustava Vrlo često: proljev, povraćanje (manje često nakon boostera)
English: Infants, 3 months to 5 months
Croatian: Dojenčad, 3 mjeseca do 5 mjeseci
English: Bactericidal antibody responses one month after the third vaccination against meningococcal reference strains were high against the fHbp, NadA and PorA P1.4 antigens at both Bexsero vaccination schedules.
Croatian: Odgovori baktericidnih protutijela mjesec dana nakon trećeg cijepljenja protiv meningokoknih referentnih sojeva bili su visoki na antigene fHbp, NadA i PorA P1.4 u obje sheme cijepljenja Bexserom.
English: At one month following a booster administered 6 months after the last dose, the percentages of seropositive subjects ranged from 87% to 100% for the two-dose schedule, and from 83% to 100% for the three-dose schedule.
Croatian: Mjesec dana nakon primjene booster doze, koju su cijepljenici primili 6 mjeseci nakon posljednje doze, postotak seropozitivnih ispitanika kretao su se u rasponu od 87% do 100% kod sheme cijepljenja dvjema dozama te od 83% do 100% kod sheme cijepljenja trima dozama.
English: It will be injected into a muscle, usually the thigh for infants or the upper arm for children, adolescents and adults.
Croatian: Cjepivo se injicira u mišić, u dojenčadi obično u bedro, a u djece, adolescenata i odraslih u nadlakticu.
English: When Bexsero was given alone, the frequency of fever was similar to that associated with routine infant vaccines administered during clinical trials.
Croatian: učestalost vrućice bila je slična onoj povezanoj s rutinskim cjepivima dojenčadi primjenjivanim tijekom kliničkih ispitivanja.
English: Percentage of adolescents with seroresponse and at least 4-fold rise in bactericidal titers one month after two doses of Bexsero administered according to different two-dose schedules - stratified by pre-vaccination titers
Croatian: Postotak adolescenata sa serološkim odgovorom i najmanje četverostrukim povećanjem baktericidnih titara jedan mjesec nakon dvije doze Bexsera primijenjenog prema različitim shemama s dvije doze - stratificirano prema titrima prije cijepljenja
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ(I) BIOLOŠKE(IH) DJELATNE(IH) TVARI I PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U
English: Adolescents (from 11 years) and adults*
Croatian: Adolescenti (od 11 godina) i odrasli*
English: Immunogenicity results at one month after three doses of Bexsero administered at 2, 3, 4 and 2, 4, 6 months of age are summarised in Table 2.
Croatian: Rezultati imunogenosti jedan mjesec nakon tri doze Bexsera primijenjene u dobi od 2, 3, 4 i 2, 4, 6 mjeseci sažeti su u Tablici 2.
English: Immunogenicity in infants 2 months to 5 months of age
Croatian: Imunogenost u dojenčadi u dobi od 2 do 5 mjeseci
English: 6 to 10 years of age fHbp
Croatian: 6 do 10 godina fHbp
English: Uncommon: pallor (rare after booster) Rare: Kawasaki syndrome
Croatian: Rijetko: Kawasakijev sindrom
English: Data on bactericidal antibody persistence at 8 months after Bexsero vaccination at 2, 3 and 4 months of age, and at 6 months after Bexsero vaccination at 2, 4 and 6 months of age (pre-booster time point) and booster data after a fourth dose of Bexsero administered at 12 months of age are summarised in Table 3.
Croatian: Podaci o postojanosti baktericidnih protutijela 8 mjeseci nakon cijepljenja Bexserom u dobi od 2, 3 i 4 mjeseca te 6 mjeseci nakon cijepljenja Bexserom u dobi od 2, 4 i 6 mjeseci (vremenska točka prije primanja boostera) i podaci o boosteru nakon četvrte doze Bexsera primijenjenog u dobi od 12 mjeseci sažeti su u Tablici
English: Children 12 months to 23 months of age should receive two injections of the vaccine followed by an additional injection (booster).
Croatian: Djeca u dobi od 12 do 23 mjeseca trebaju primiti dvije injekcije cjepiva, a nakon toga još jednu dodatnu injekciju (docjepljivanje).
English: pre-vaccination titer ≥1:4
Croatian: titar prije cijepljenja ≥1:4
English: 0.5 ml suspension in a pre-filled syringe (Type I glass) with a plunger stopper (Type I bromobutyl rubber) and with a protective tip cap (Type I or Type II rubber) with or without needles.
Croatian: 0,5 ml suspenzije u napunjenoj štrcaljki (staklo tipa I) s čepom klipa (bromobutilna guma tip I)
English: In a phase 3 clinical study, children and adolescents 2 through 17 years of age with complement deficiencies (40), with asplenia or splenic dysfunction (107), and age-matched healthy subjects (85) received two doses of Bexsero two months apart.
Croatian: U kliničkom ispitivanju faze 3, djeca i adolescenti u dobi od 2 do 17 godina s nedostacima komplementa (40), asplenijom ili poremećajima funkcije slezene (107), te zdravi ispitanici iste dobi
English: Serum bactericidal antibody responses in adolescents one month after two doses of Bexsero administered according to different two-dose schedules and persistence of bactericidal antibody 18 to 23 months after the second dose
Croatian: Odgovori serumskih baktericidnih protutijela u adolescenata jedan mjesec nakon dvije doze Bexsera primijenjene prema različitim shemama s dvije doze i postojanost baktericidnih protutijela 18 do 23 mjeseca nakon druge doze
English: At approximately 4 years after the two-dose primary series, the percentages of subjects with hSBA ≥ 1:5 generally declined from a range across strains of 68% to 100% after the second dose to a range across strains of 9% to 84%.
Croatian: Približno 4 godine nakon dvije doze primarne serije imunizacije postoci ispitanika koji su imali hSBA ≥ 1:5 općenito su se smanjili, te su se sa raspona od 68% do 100% kod svih sojeva nakon druge doze spustili na raspon od 9% do 84% kod svih sojeva.
English: Seroresponse rates and percentages of subjects with at least a 4-fold increase in hSBA titer from baseline to one month after the second dose of Bexsero are summarised in Table 8.
Croatian: Stope seroloških odgovora i postotci ispitanika s najmanje četverostrukim povećanjem titra hSBA od početne vrijednosti do jedan mjesec nakon druge doze Bexsera, sažete su u Tablici 8.
English: Not known: syncope or vasovagal responses to injection, meningeal irritation (signs of meningeal irritation, such as neck stiffness or photophobia, have been sporadically reported shortly after vaccination.
Croatian: Nepoznato: sinkopa ili vazovagalni odgovori na injekciju, meningealna iritacija (znakovi meningealne iritacije kao što su ukočenost vrata ili fotofobija prijavljeni su sporadično ubrzo nakon cijepljenja.
English: At approximately 7.5 years after the two-dose primary series, the percentages of subjects with hSBA ≥ 1:4 declined, ranging across strains from 29% to 84%.
Croatian: Približno 7,5 godina nakon dvije doze primarne serije imunizacije postoci ispitanika koji su imali hSBA ≥ 1:4 su se smanjili, te su se kod svih sojeva kretali u rasponu od 29% do 84%.
English: Serum bactericidal antibody responses following a booster at 12 months after a primary series administered at 2, 3 and 4 or 2, 4 and 6 months of age, and persistence of bactericidal antibody one year after the booster
Croatian: Tablica 3. Odgovori serumskih baktericidnih protutijela nakon boostera 12 mjeseci nakon primarnog cijepljenja provedenog u dobi od 2, 3 i 4 ili 2, 4 i 6 mjeseci i postojanost baktericidnih protutijela jednu godinu nakon boostera
English: The need for, and timing of, further booster doses has not yet been determined.
Croatian: Vidjeti dio 5.1. Potreba za daljnjim booster dozama i njihov raspored davanja još nije određen.
English: Bexsero is not expected to provide protection against all circulating meningococcal group B strains (see section 5.1).
Croatian: Bexsero nije predviđen za pružanje zaštite od svih cirkulirajućih sojeva meningokoka grupe B
English: Serum bactericidal antibody responses following Bexsero vaccination at 6 and 8 months of age or 13 and 15 months of age and persistence of bactericidal antibody one year after the two doses at 13 and 15 months of age
Croatian: Tablica 4. Odgovori serumskih baktericidnih protutijela nakon cijepljenja Bexserom u dobi od 6 i 8 mjeseci ili 13 i 15 mjeseci i postojanost baktericidnih protutijela jednu godinu nakon dvije doze u dobi od 13 i 15 mjeseci
English: Serum bactericidal antibody responses at 1 month following the third dose of Bexsero given at 2, 3, 4 or 2, 4, 6 months of age
Croatian: Tablica 2. Odgovori serumskih baktericidnih protutijela 1 mjesec nakon treće doze Bexsera primijenjene u dobi od 2, 3, 4 ili 2, 4, 6 mjeseca
English: A two-dose schedule followed by a booster has been evaluated in infants 3 months to 5 months of age in a clinical study.
Croatian: Shema cijepljenja dvjema dozama nakon kojih slijedi booster doza ocjenjivala se u kliničkom ispitivanju provedenom u dojenčadi u dobi od 3 mjeseca do 5 mjeseci.
English: Adolescents (from 11 years of age) and adults should receive two injections of the vaccine.
Croatian: Adolescenti i odrasli koji prvu dozu prime u dobi od najmanje 11 godina Adolescenti (od 11 godina nadalje) i odrasli trebaju primiti dvije injekcije cjepiva.